Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

Zenopa made me feel at ease the first time I spoke with them. I have never used a recruitment agency before so was unsure of what was expected of me.
Julie, 2012

GlaxoSmithKline submits personalised melanoma therapy for approval

12 February 2013 11:22 in Pharmaceutical Company Product News

GlaxoSmithKline has submitted a marketing authorisation application to the European Medicines Agency (EMA) for approval of its new melanoma drug trametinib.

The compound is intended for use as a monotherapy and in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

GlaxoSmithKline's request for accelerated assessment of this application has already been approved by the EMA's Committee for Medicinal Products for Human Use (CHMP), based on encouraging data from clinical trials.

An application that has been granted accelerated assessment will have a maximum review time of 150 days, though this could be extended should the CHMP or GlaxoSmithKline deem it appropriate.

Dr Rafael Amado, head of oncology research and development at GlaxoSmithKline, said: "We are planning further regulatory submissions based on these data, in the US and other countries in the coming months."

Last week, the company announced its support for AllTrials, a campaign aimed at improving clinical trial transparency within the pharmaceutical industry.ADNFCR-8000103-ID-801538780-ADNFCR

Other news stories from 12/02/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd